Navigation Links
Reportlinker Adds France Pharmaceutical Market Overview - Austerity measures will impact pharmaceutical market growth
Date:1/11/2011

NEW YORK, Jan. 11, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

France Pharmaceutical Market Overview – Austerity measures will impact pharmaceutical market growth

http://www.reportlinker.com/p0360215/France-Pharmaceutical-Market-Overview-–--Austerity-measures-will-impact-pharmaceutical-market-growth.html

Introduction

The prescription pharma market in France was valued at $38.8bn in sales in 2009, having by 3.1% (CAGR; 2005–09). Key growth drivers include growing use of chronic high-value innovative treatments driven by an aging population, high public healthcare expenditure as proportion of total healthcare expenditure, physician preference for prescribing branded drugs as well as high patient brand loyalty.

Features and benefits

* Overview of socioeconomic and demographic trends, healthcare system, regulation, pricing and reimbursement and intellectual property in France

* Assesses the size of the French pharmaceutical market by prescribing setting, therapy area, leading brands and by leading companies

* Examines the French generics and biosimilars landscape in terms of regulatory issues, level of penetration, key players and degree of brand erosion

* Quantifies the R&D and manufacturing infrastructure for the leading pharmaceutical companies, including key metrics and domestic M&A analysis

Highlights

Despite having a higher birth rate than most European countries, with its ageing population France is encountering difficulties in handling its health account deficit, a situation made worse by the economic downturn. Hence France has turned towards social system reforms and austerity measures. Despite having a favourable market for innovative and expensive drugs a range of cost-cutting measures such as pricing and reimbursement cuts will have a negative impact on the French pharmaceutical market. Once considered the immature generics market, France has considerably increased its generics uptake although there is still a significant scope for improvement. Physicians' resistance to generics use remains the greatest obstacle with adequate physicians' financial incentives necessary in the future.

Your key questions answered

* Evaluate the evolving regulatory landscape and the impact of pricing and reimbursement controls on market access in France

* Quantify the size and growth of the prescription pharmaceutical market in France, analyzing key therapy areas, brands and companies

* Assess drivers and resistors of generic and biosimilars uptake in France

To order this report:

: France Pharmaceutical Market Overview – Austerity measures will impact pharmaceutical market growth

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds Innovative Drug Discovery in Emerging Markets
2. Reportlinker Adds Chugai Pharmaceutical Co., Ltd: PharmaVitae Profile
3. Reportlinker Adds Cosmetic Surgery Products
4. Reportlinker Adds Regenerative Medicine Markets
5. Reportlinker Adds Womens Health Diagnostic Testing
6. Reportlinker Adds 2010-2015 In-depth Research Report on China Sodium Fluoride Industry
7. Reportlinker Adds E7: The Outlook for Pharmaceuticals to 2012
8. Reportlinker Adds The Outlook for Pharmaceuticals in Central Asia
9. Reportlinker Adds The Outlook for Pharmaceuticals in Western Europe
10. Reportlinker Adds Mammography World Markets
11. Reportlinker Adds Molecular Diagnostics in Cancer Testing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... -- Mast Therapeutics, Inc. (NYSE MKT: MSTX), ... cell disease and heart failure, today announced the pricing ... a price to the public of $0.275 per unit. ... common stock and one warrant to purchase one share ... of $0.42 per share. The warrants are exercisable six ...
(Date:2/10/2016)... Feb. 10, 2016  Silicon Biosystems Menarini Inc., ... that help uncover the biological complexities of disease ... a developer of innovative technologies for genomics research, ... aimed at enabling translational researchers to obtain high-quality ... hundred tumor and normal cells in an optimized ...
(Date:2/10/2016)... Feb. 9, 2016 CTI BioPharma Corp. ... an update regarding the clinical studies being conducted ... for pacritinib. Following the issuance of the Company,s ... clinical hold issued by the U.S. Food and ... Company received an oral communication from the FDA ...
Breaking Medicine Technology:
(Date:2/10/2016)... Angeles, CA (PRWEB) , ... February 10, 2016 ... ... Programming (NLP) practitioner, is known locally for a series of therapeutic sessions to ... in-the-moment in their characters and in their lives. The series, known as “Mindfulness ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... unveiling its revolutionary new 2.0 version at the International Roofing Expo in Orlando, ... power of the world's most advanced weather technology in the hands of consumers, ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... master charity program created to assist the local community. Pledging to select a ... and nonprofit organizations in the area. Their goal is to bring community awareness ...
(Date:2/10/2016)... ... ... Ongoing news of the ravages of traumatic brain injury (TBI) among former ... takes a closer look at cases of TBI being managed by their members. The ... the aging population, and identifies the challenges associated with their care. , During the ...
(Date:2/10/2016)... ... February 10, 2016 , ... Armune BioScience signed a ... network of laboratory service centers across the country. Launched in April of 2015, Apifiny ... detection of prostate cancer. Apifiny order volume exceeded 3,000 tests in 2015. Primary care ...
Breaking Medicine News(10 mins):